Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has released data from its HYPER-H21-3 human study. The company noted that data from its simulated pulmonary hypertension clinical study indicate positive safety and efficacy findings. Specifically, results show a tendency (p=0.1) during 15 minutes of simulated low levels of oxygen (hypoxia) for reduced pulmonary artery systolic pressure (“PASP”) with DehydraTECH-CBD treatment versus placebo. According to the announcement, PASP was significantly attenuated by about 5 mmHg or 41% overall (p=0.045) in male participants, which could indicate potential differences by sex in responsiveness to CBD treatment under hypoxic stress conditions. The company noted that this data supports similar findings from previous successful studies, all of which support Lexaria’s anticipated move to begin the process of seeking approval for the technology from the U.S. Food and Drug Administration. The company has gathered significant evidence of DehydraTECH-CBD’s ability to reduce blood pressure across a wide variety of situations. The data from the most recent study will be analyzed in order to determine the direction of the company’s upcoming research looking into the efficacy of DehydraTECH-CBD use for the management of elevations in pulmonary arterial pressure under hypoxic conditions, related hypoxemic pathologies and pulmonary hypertension.

To view the full press release, visit https://cnw.fm/JPIGS

About Lexaria Bioscience Corp.

Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption with cannabinoids and nicotine by 5 to 10 times — in some instances with cannabinoids by as much as 27x compared to standard industry formulations — reduce time of onset from one to two hours to minutes and mask unwanted tastes. The delivery systems are also being evaluated for orally administered, anti-viral drugs; nonsteroidal, anti-inflammatory drugs (“NSAIDs”); PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 24 patents granted and more than 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com. 

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.